Reference

Studies on the metabolites of T-2588 in serum and urine in phase I study

Studies on the metabolites of T-2588 in serum and urine in phase I study. Saikawa, Isamu; Tai, Masaru; Sugimoto, Yumiko (Res. Lab., Toyama Chem. Co., Ltd., Toyama 930, Japan). Chemotherapy (Tokyo), 34(Suppl. 2), 158-65 (Japanese) 1986. CODEN: NKRZAZ. ISSN: 0369-4682. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The metab. of T-2588 (I) [82547-81-7], a new esterified oral cephem, was studied in serum and urine in human subjects. Besides T-2525 [82547-58-8], the parent compd. of T-2588, T-2525 A [104691-34-1] was detected in serum and urine. Urinary recoveries of T-2525 and T-2525 A were higher in the non-fasting state than in the fasting state. Urinary recoveries of T-2525 and T-2525 A were not affected by multiple administration.In this experiment, several chemicals are used like 82547-81-7 and 75-98-9 Pivalic acid [75-98-9], the metabolite derived from the ester moiety of T-2588, was detected in serum and urine as the free acid or conjugate. 5-Methyl-1H-tetrazole (T-2588 F) [4076-36-2], was detected in urine. .

Fundamental and clinical studies of T-2588

Fundamental and clinical studies of T-2588. Totsuka, Kyoichi; Ohi, Satoshi; Kumada, Teppei; Shimizu, Kihachiro (Dep. Intern. Med., Tokyo Women's Med. Coll., Tokyo, Japan).Some commonly used reagents like 82547-58-8 and 82547-81-7 are used in this experiment. Chemotherapy (Tokyo), 34(Suppl. 2), 331-5 (Japanese) 1986. CODEN: NKRZAZ. ISSN: 0369-4682. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The pharmacokinetics of the cephem antibiotic T-2588 (I) [82547-81-7] and its metabolite T-2525 (II) [82547-58-8] was studied in healthy humans after oral administration of 100 mg I, peak serum I levels were obtained 2-3 h after administration and averaged 1.06 mg/mL. The mean urinary recovery rate of II in 6 h was 23.16%. In subjects pretreated with profenicid, peak serum levels of ~2.02 mg II/mL were obsd. 3 h after I administration and the mean urinary recovery rate of II in 6 h was 16.58%. The clin. effects of I are reported. .